Antitumor effect of a novel humanized MUC1 antibody-drug conjugate on triple-negative breast cancer

Antitumor effect of a novel humanized MUC1 antibody-drug conjugate on triple-negative breast cancer

Breast cancer is the most common malignant cancer in women. Triple-negative breast cancer (TNBC) has a poorer prognosis than other subtypes and is challenging to treat. MUC1 is a therapeutic target in breast and pancreatic cancer. We developed a novel humanized antibody that specifically binds MUC1...

Full description

Bibliographic Details
Main Authors:	Lan Li, Jiawei Cao, Chunyan Chen, Yaqian Qin, Licai He, Haihua Gu, Guang Wu
Format:	Article
Language:	English
Published:	Elsevier 2023-04-01
Series:	Heliyon
Subjects:	Mucin1 Humanized antibody Antibody-drug conjugate MMAE TNBC
Online Access:	http://www.sciencedirect.com/science/article/pii/S240584402302371X

Similar Items

Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model
by: Guang Wu, et al.
Published: (2022-12-01)

Clinical pharmacology of vc-MMAE antibody–drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies
by: Chunze Li, et al.
Published: (2020-01-01)

Antibody-Drug Conjugates Targeting Tumor-Specific Mucin Glycoepitopes
by: Julyanne Brassard, et al.
Published: (2022-11-01)

Surface-Available HER2 Levels Alone Are Not Indicative of Cell Response to HER2-Targeted Antibody–Drug Conjugate Therapies
by: Molly Major, et al.
Published: (2024-06-01)

Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer
by: Efrat T. Harel, et al.
Published: (2019-11-01)

Second-line antibody-drug conjugates for the treatment of metastatic human papillomavirus-independent gastric-type adenocarcinoma of cervix: The Singapore experience
by: Daniel Jia Ming Ang, et al.
Published: (2025-04-01)

Insights into uveitis from Brentuximab vedotin in refractory Hodgkin’s lymphoma: a case report and brief review
by: Mengyuan Liu, et al.
Published: (2024-08-01)

Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes
by: Hsuan-Ping Chang, et al.
Published: (2023-04-01)

Toward Homogenous Antibody Drug Conjugates Using Enzyme-Based Conjugation Approaches
by: Ahmad Fawzi Hussain, et al.
Published: (2021-04-01)

A Novel Dual-Payload ADC for the Treatment of HER2+ Breast and Colon Cancer
by: Candice Maria Mckertish, et al.
Published: (2023-07-01)

Site-Specific Antibody–Drug Conjugates in Triple Variable Domain Fab Format
by: Dobeen Hwang, et al.
Published: (2020-05-01)

Research on therapeutic clinical trials including immunotherapy in triple-negative breast cancer: a bibliometric analysis
by: Qi Xu, et al.
Published: (2024-10-01)

Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy
by: Chi Hun Song, et al.
Published: (2023-11-01)

An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy
by: Alberto Juan, et al.
Published: (2020-08-01)

HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel
by: Hui Lyu, et al.
Published: (2023-09-01)

Novel anticarcinoembryonic antigen antibody–drug conjugate has antitumor activity in the existence of soluble antigen
by: Daisuke Shinmi, et al.
Published: (2017-04-01)

Antibody Drug Conjugates for Cancer Therapy
by: S M Gheibi hayat, et al.
Published: (2017-07-01)

Antibody Conjugates: From Heterogeneous Populations to Defined Reagents
by: Patrick Dennler, et al.
Published: (2015-08-01)

Bispecific antibody drug conjugates: Making 1+1>2
by: Yilin Gu, et al.
Published: (2024-05-01)

Possible Therapeutic Utility of anti-Cell Adhesion Molecule 1 Antibodies for Malignant Pleural Mesothelioma
by: Man Hagiyama, et al.
Published: (2022-07-01)

Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma
by: Suheil Albert Atallah-Yunes, et al.
Published: (2022-01-01)

Enzyme-Based Labeling Strategies for Antibody–Drug Conjugates and Antibody Mimetics
by: Georg Falck, et al.
Published: (2018-01-01)

Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations
by: Hyunbo Shim
Published: (2020-02-01)

Antibody–Biopolymer Conjugates in Oncology: A Review
by: Vivek P. Chavda, et al.
Published: (2023-03-01)

A Potential Antibody–Drug Conjugate Targeting Human LIV1 for the Treatment of Triple-Negative Breast Cancer
by: Wei Zhang, et al.
Published: (2023-09-01)

Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
by: Yahya Ashraf, et al.
Published: (2019-02-01)

Identification of CD73 as the Antigen of an Antigen-Unknown Monoclonal Antibody Established by Exosome Immunization, and Its Antibody–Drug Conjugate Exerts an Antitumor Effect on Glioblastoma Cell Lines
by: Takahiro Anzai, et al.
Published: (2022-07-01)

Site‐Selective Tyrosine Reaction for Antibody‐Cell Conjugation and Targeted Immunotherapy
by: Hongfei Chen, et al.
Published: (2024-02-01)

Progresses in research and development of antibody-drug conjugate
by: Wu Gang, et al.
Published: (2021-12-01)

Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine
by: Saif Khan, et al.
Published: (2024-12-01)

Antibody conjugates and malignant disease /
by: 399966 Magerstadt, Michael
Published: (1990)

Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy
by: Shabnam Malik, et al.
Published: (2024-08-01)

Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer
by: Mehrnoosh Pauls, et al.
Published: (2022-07-01)

Antibody drug conjugates in the clinic
by: Edidiong Udofa, et al.
Published: (2024-11-01)

Interrogating heterogeneity of cysteine-engineered antibody-drug conjugates and antibody-oligonucleotide conjugates by capillary zone electrophoresis-mass spectrometry
by: Tian Xu, et al.
Published: (2023-12-01)

Exploration of the antibody–drug conjugate clinical landscape
by: Heather Maecker, et al.
Published: (2023-12-01)

Antibody conjugates in neuroblastoma: a step forward in precision medicine
by: Jihane Balla, et al.
Published: (2025-03-01)

Anti-CD47 Monoclonal Antibody–Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers
by: Yingnan Si, et al.
Published: (2021-08-01)

Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma
by: Waqqas Tai, et al.
Published: (2022-03-01)

Antibody-drug conjugates for cancer therapy
by: Anna Grzywa
Published: (2021-11-01)